KineMed, Inc., a platform-based drug development and advanced medical diagnostics company announced today the signing of a compound evaluation agreement with Sosei Co. Ltd. (4565, Tokyo Stock Exchange MOTHERS Index), a leading Japanese biopharmaceutical company focused on drug development.

Under the terms of the deal, KineMed will screen numerous molecules provided by the library of Sosei's Drug Reprofiling Platform® (DRP®) using KineMed’s proprietary in vivo KineMarker™ assays. The compounds have all completed preclinical development and most have advanced through Phase I or Phase II clinical testing and have favorable safety profiles. No compounds were withdrawn from development for reasons of serious toxicity. KineMed will use its assays to determine whether any of the compounds have potential for indications other than those for which they were originally developed.

“We are excited about applying our in vivo screening technology to these compounds to find new potential indications,” said David Fineman, President and CEO of KineMed. “Sosei has provided an ample number of candidates from its Drug Reprofiling Platform to work with, and we look forward to creating success with our new partner.”

Chizuko Koseki, Vice President Research Planning and Head of DRP of Sosei, stated, “The potential to gain added value through KineMed’s repurposing approach is significant and may address multiple unmet medical needs. We are hopeful that KineMed’s screening will expand the therapeutic and economic potential of many of the DRP compounds.”

About KineMed, Inc.
KineMed, Inc. provides an exclusive set of tools for measuring the dynamics of therapeutic response to drugs in the intact organism, both in animals and humans. KineMed seeks to enable the discovery of entirely new uses for compounds by revealing activity across a variety of disease states. KineMed’s technology expedites the drug development process and provides diagnostic insight into conditions such as insulin resistance and blood disorders. For further information about KineMed, please visit: www.kinemed.com.

About Sosei Co. Ltd.
Sosei Co. Ltd., founded in 1990 by Shinichi Tamura, the ex-CEO of Genentech Japan, is a leading Japanese biopharmaceutical company with significant expertise in drug development. It enriches its core product pipeline by in-licensing compounds from Western and Japanese companies, by its distinctive Drug Reprofiling Platform® (DRP®) and through new molecular entity (NME) research programmes in collaboration with biopharmaceutical companies and universities both in Japan and the West. Sosei is also developing its own sales and marketing organization in Japan. The company is capitalizing on its extensive global network established over the past 10 years in its successful technology transfer business. For further information about Sosei, please visit: www.sosei.com.

For further information about KineMed, please visit: http://www.kinemed.com

CONTACT:
David Fineman, President and CEO KineMed +1-510-655-6525 ext. 102;
or Kathy Nugent, Ph.D. (media), Burns McClellan, +1-212-213-0006